Hepatitis B immunisation in Britain: Time to change?

British Medical Journal

Volumn 332, Issue 7545, 2006, Pages 804-805

  Banatvala, Jangu ^a   Van Damme, Pierre ^b   Emiroglu, Nedret ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

DISEASE TRANSMISSION; DRUG COST; EDITORIAL; ENDEMIC DISEASE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMIGRATION; IMMUNIZATION; INFECTION PREVENTION; MASS SCREENING; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED KINGDOM; VACCINATION; WORLD HEALTH ORGANIZATION; MIGRATION; ORGANIZATION AND MANAGEMENT;

EMIGRATION AND IMMIGRATION; GREAT BRITAIN; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; PREVALENCE;

EID: 33645821641     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38797.621516.47     Document Type: Editorial

References (13)

1. WHO Expanded Programme on Immunisation, Global Advisory Group. Wkly Epidemiol Rec 1992;3:11-6.
2. Beeching NJ. Hepatitis B infections: universal immunisation should be preferred in Britain. BMJ 2004;329:1059-60.
3. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clinical Virol 2004;29:211-20.
4. Department of Health. Getting ahead of the curve. A strategy for combating infectious diseases (including other aspects of health protection). London: DoH, 2002.
5. Van Damme P, Van Herck K, Leuridan E, Vorsters A. Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. 2004. www.eurosurveillance.org/ew/2004/041118.asp (accessed 2 Mar 2006).
6. Chrystie I, Sumner D, Palmer S, Kenney A, Banatvala J. Screening of pregnant women for evidence of current hepatitis B infection: selective or universal? Health Trends 1992;24:1.
7. Aweis D, Brabin BJ, Beeching NJ, Bunn JEG, Cooper C, Gardner K, et al. Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool. Commun Dis Public Health 2001;4:240-5.
8. Banatvala JE, Van Damme P. Hepatitis B vaccine-do we need boosters? J Viral Hepatitis 2003;10:1-6.
9. McVernon J, Andres N, Slack MP, Ramsay ME. Risk of vaccine failure after haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3.
10. Wallace LA, Bramley JC, Ahmed S, Duff R, Hutchinson SJ, Carman WF, et al. Determinants of universal adolescent hepatitis B vaccine uptake. Arch Dis Child 2004;89:1041-2.
11. Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two and three dose hepatitis B vaccination regimens in adolescent: antibody responses, safety and immunologic memory. Paediatrics 2001;4:626-31.
12. Viral Hepatitis Prevention Board. Can the United Kingdom control viral hepatitis. VHPB meeting, Edinburgh, Nov 2005. www.vhpb.org (accessed 31 Jan 2006).
13. Beutels P. Economic evaluations of hepatitis B immunizations: a global review of recent studies (1994-2000). Health Econ 2001;10:751-74.